English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu
“The disease-free survival data revealed is profound,” said Roy S. Herbst, M.D., Ph.D., Chief of Medical Oncology at YCC and Smilow Cancer Hospital, Associate Cancer Center Director for Translational Research at YCC, and co-leader of the study. “The hope was osimertinib would provide an alternative to chemotherapy for patients with early-stage lung cancer. Instead, we were thrilled to discover an incredible benefit for these patients in the fight against this deadly disease.”
The trial results showed that osimertinib offered a two-year, 89% DFS for patients with resected lung cancer (stage IB/II/IIIA) compared to a DFS rate of 53% in patients randomized to treatment with placebo, with manageable side effects. Disease-free survival measures the time from randomization to first sign of cancer recurrence or death. In this trial, patients treated with osimertinib had a 79% reduction in the risk of their cancer returning or death. The study will continue to follow patients for overall survival outcomes.
Osimertinib, an oral, daily medication, is a third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor that shuts down activity of specific genetic mutations that contribute to NSCLC in a subset of patients with the disease. In western populations about 10-15% of patients have these mutations, compared to 30-40% of lung cancer patients in Asia. Many lung cancer patients with EGFR mutations have never smoked cigarettes.
Osimertinib was first approved for use in EGFR mutation-positive advanced lung cancer in the United States in 2015 and is now approved worldwide for treament in this setting. The ADAURA clinical trial, conducted worldwide with 682 patients, is the first study of osimertinib in non-metastatic EGFR mutation-positive lung cancer.
Patients included in the clinical trial had surgery to remove their lung tumors and, in some cases, also received chemotherapy. The interim analysis showed DFS was consistent in patients using osimertinib whether or not they had prior chemotherapy.
“Osimertinib is much more specifically targeted to EGFR mutations than older generations of EGFR tyrosine kinase drugs,” said Herbst. “Therefore, it helps patients avoid recurrence of their cancer in the liver, lung, and brain.”
Herbst has followed the development of these drugs since 1997, when the first generation of the drug was developed and tested. “My career is marked by study and use of generations of EGFR inhibitor therapies, and we can now show that science and biologic medicine is making a huge impact in the earliest stages of lung cancer,” said Herbst, adding: “It’s incredible news.”
This study was funded by AstraZeneca.
About Yale Cancer Center and Smilow Cancer Hospital Yale Cancer Center (YCC) is one of only 51 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Smilow Cancer Hospital is accredited by the Commission on Cancer, a Quality program of the American College of Surgeons. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
# # #
Original post https://alertarticles.info
